Your browser doesn't support javascript.
loading
Outstanding improvement of the advanced lipoprotein profile in subjects with new-onset type 1 diabetes mellitus after achieving optimal glycemic control.
Castelblanco, Esmeralda; Hernández, Marta; Ortega, Emilio; Amigó, Núria; Real, Jordi; Granado-Casas, Minerva; Miñambres, Inka; López, Carolina; Lecube, Albert; Bermúdez-López, Marcelino; Alonso, Núria; Julve, Josep; Mauricio, Didac.
Afiliação
  • Castelblanco E; Department of Internal Medicine, Endocrinology, Metabolism and Lipid Research Division, Washington University School of Medicine, St Louis, MO 63110, USA; Unitat de Suport a la Recerca Barcelona, Institut Universitari d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAP Jordi Gol), 08007 Bar
  • Hernández M; Department of Endocrinology & Nutrition, Hospital Arnau de Vilanova & Institut d'Investigació Biomédica de Lleida (IRB Lleida), 25198 Lleida, Spain.
  • Ortega E; Department of Endocrinology & Nutrition, Diabetes Unit, Hospital Clínic de Barcelona, 08036 Barcelona, Spain; Institut d'investigacions biomèdiques August Pi i Sunyer, 08036 Barcelona, Spain; Center for Biomedical Research on Pathophysiology of Obesity and Nutrition (CIBEROBN), Instituto de Salu
  • Amigó N; Biosfer Teslab, SL, Reus, Spain; Metabolomics Platform, Rovira i Virgili University (URV), Instituto de Investigación Sanitaria Pere Virigili (IISPV), 43007 Tarragona, Spain.
  • Real J; Unitat de Suport a la Recerca Barcelona, Institut Universitari d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAP Jordi Gol), 08007 Barcelona, Spain; Center for Biomedical Research on Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), 28022 Madri
  • Granado-Casas M; Department of Endocrinology & Nutrition, Hospital Arnau de Vilanova & Institut d'Investigació Biomédica de Lleida (IRB Lleida), 25198 Lleida, Spain; Center for Biomedical Research on Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), 28022 Madrid,
  • Miñambres I; Center for Biomedical Research on Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), 28022 Madrid, Spain; Department of Endocrinology & Nutrition, Hospital de la Santa Creu i Sant Pau & Sant Pau Biomedical Research Institute (IIB Sant Pau), 08041 B
  • López C; Department of Endocrinology & Nutrition, Hospital Arnau de Vilanova & Institut d'Investigació Biomédica de Lleida (IRB Lleida), 25198 Lleida, Spain.
  • Lecube A; Department of Endocrinology & Nutrition, Hospital Arnau de Vilanova & Institut d'Investigació Biomédica de Lleida (IRB Lleida), 25198 Lleida, Spain; Center for Biomedical Research on Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), 28022 Madrid,
  • Bermúdez-López M; Vascular and Renal Translational Research Group, Institute for Biomedical Research Dr. Pifarré Foundation, IRBLleida and RedinRen RETIC, ISCIII, 25198 Lleida, Spain.
  • Alonso N; Center for Biomedical Research on Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), 28022 Madrid, Spain; Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain; Department of Endocrinology & Nutrition, Hospital Universitari Germa
  • Julve J; Center for Biomedical Research on Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), 28022 Madrid, Spain; Sant Pau Biomedical Research Institute (IIB Sant Pau), 08041 Barcelona, Spain. Electronic address: jjulve@santpau.cat.
  • Mauricio D; Unitat de Suport a la Recerca Barcelona, Institut Universitari d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAP Jordi Gol), 08007 Barcelona, Spain; Center for Biomedical Research on Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), 28022 Madri
Diabetes Res Clin Pract ; 182: 109145, 2021 Dec.
Article em En | MEDLINE | ID: mdl-34785302
ABSTRACT

AIMS:

The impact of glycemic optimization on lipoprotein subfraction parameters in apparently normolipidemic subjects with new-onset type 1 diabetes mellitus (T1D) was examined.

METHODS:

We evaluated the serum lipid and advanced lipoprotein profiles in twenty subjects at onset of T1D and twenty non-diabetic controls by laboratory methods and 1H NMR spectroscopy shortly after diabetes diagnosis (baseline), and after achieving optimal glycemic control (HbA1c ≤ 7.0%).

RESULTS:

Advanced lipoprotein analysis revealed a significant reduction from baseline in serum concentrations of triglycerides (TG), cholesterol (C), and apolipoprotein (Apo)B-containing lipoproteins of treated subjects (VLDL-TG -21%, IDL-TG -30%, LDL-TG -34%, LDL-TG -36%, P < 0.05; VLDL-C -23%, IDL-C -44%, LDL-C -16%; p < 0.05). Decreased VLDL and LDL lipids were mainly attributed to concomitant reductions in the concentration of medium-sized VLDL (-36%) and medium-sized LDL (-31%) and, to a lesser extent, to large-sized LDL (-14%). Notably, proatherogenic IDL characteristics and related surrogates of atherogenicity were resolved upon achievement of optimal glycemic status. Moreover, the concentration of HDL-TG was also reduced (-18%) at follow-up.

CONCLUSIONS:

Our data showed that the achievement of optimal glycemic control after T1D onset corrected hidden derangements in ApoB-containing lipoproteins (particularly IDL) and HDL-TG that are related to higher cardiovascular risk in poorly controlled T1D.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 1 Limite: Humans Idioma: En Revista: Diabetes Res Clin Pract Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 1 Limite: Humans Idioma: En Revista: Diabetes Res Clin Pract Ano de publicação: 2021 Tipo de documento: Article